SPECT/CT for the Characterization of Renal Masses

Description

This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.

Conditions

Kidney Neoplasm, Renal Mass

Talk to us

Study Overview

On this page

Study Details

Study overview

This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.

SPECT/CT for the Characterization of Renal Masses: Impact on Clinical Decision Making

SPECT/CT for the Characterization of Renal Masses

Condition
Kidney Neoplasm
Intervention / Treatment

-

Contacts and Locations

Los Angeles

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States, 90095

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Performance status Eastern Cooperative Oncology Group (ECOG) \< 2.
  • * Life expectancy (\> 1 year).
  • * New diagnosis of a renal tumor (within past 3 months).
  • * Measurable, predominantly (\> 80%) solid renal neoplasm between 1.5-5.0 cm.
  • * Lesion concerning for kidney cancer bases on a contrast-enhanced CT or magnetic resonance imaging (MRI).
  • * No definitive evidence of metastatic disease.
  • * Does not require urgent surgical treatment.
  • * Candidate for surgical, ablative, and surveillance approach.
  • * Willingness to obtain more information to aid decision-making.
  • * Understanding and willingness to provide consent.
  • * Presence of multiple solid renal tumors.
  • * A prior needle biopsy of the mass resulting in histologic diagnosis.
  • * A prior diagnosis of kidney cancer.
  • * Presence of an active, untreated, non-renal malignancy.
  • * History of bleeding diathesis or recent bleeding episode.
  • * Prior surgery or radiation therapy to the kidney.
  • * Unwillingness to fill out questionnaires.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Jonsson Comprehensive Cancer Center,

Brian Shuch, PRINCIPAL_INVESTIGATOR, UCLA / Jonsson Comprehensive Cancer Center

Study Record Dates

2025-12-31